RICERCA
AUTORI
RIVISTE
Sfoglia per AUTORE
TRENTIN L
Collezione AO Cuneo
Items : 43
Patients' preferences for chronic lymphocytic leukemia treatment: The CHOICE study. in Hematological oncology / Hematol Oncol. 2024 Jan;42(1):e3216. doi: 10.1002/hon.3216. Epub 2023 Sep 29.
2024
AO Cuneo
AOU Città della Salute di Torino
AOU Novara
Molica S; Malgieri S; Iannella E; Caira M; Finsinger P; Gualberti G; Reda G; Gozzetti A; Coscia M; Vallisa D; Pane F; Cuneo A; Albano F; Zamprogna G; Mauro FR; Trentin L; Albi E; Sportoletti P; Gaidano G; Laurenti L; Chiarenza A;
Continuous venetoclax in treatment-naive TP53 disrupted patients with chronic lymphocytic leukemia: A chronic lymphocytic leukemia campus study. in American journal of hematology / Am J Hematol. 2023 Sep;98(9):E237-E240. doi: 10.1002/ajh.27009. Epub 2023 Jun 29.
2023
AO Cuneo
AOU Città della Salute di Torino
AOU Alessandria
Trentin L; Cuneo A; Foà R; Ghia P; Coscia M; Laurenti L; Molica S; Zatta I; Cavarretta CA; Angotzi F; Cellini A; Ruocco V; Rigolin GM; Sportoletti P; Trimarco V; Murru R; Marchetti M; Pietrasanta D; Cibien F; Vitale C; Sanna A; Derenzini E; Proietti G; Ferrarini I; Reda G; Mauro FR; Scarfò L; Gentile M; Farina L; et alii...
Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter "Real-World" study. in American journal of hematology / Am J Hematol. 2023 Feb;98(2):E24-E27. doi: 10.1002/ajh.26779. Epub 2022 Nov 25.
2023
AO Cuneo
AOU Città della Salute di Torino
AOU Alessandria
AOU Novara
Levi S; Trentin L; Foà R; Cuneo A; Herishanu Y; Gentile M; Perry C; Gattei V; Gaidano G; Rossi D; Neri A; Olivieri J; Bomben R; Zucchetto A; Visentin A; Loseto G; Pietrasanta D; Chiarenza A; Braester A; Murru R; Aviv A; Varettoni M; Coscia M; Tadmor T; Shvidel L; Sportoletti P; Laurenti L; Reda G; Ruchlemer R; et alii...
SARS-CoV-2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID-19 cohort. in Hematological oncology / Hematol Oncol. 2023 Feb;41(1):128-138. doi: 10.1002/hon.3092. Epub 2022 Oct 25.
2023
ASL Torino 5
AOU Alessandria
AO Cuneo
AOU Città della Salute di Torino
ASL Cuneo 1
AOU Novara
Coviello E; Cilloni D; Passamonti F; Corradini P; Bertù L; Guidetti A; Visco C; Pagano L; Gherlinzoni F; Galimberti S; Tisi MC; Cudillo L; Gentile M; Mohamed S; Visani G; Federici AB; Della Porta MG; Mauro FR; Gambacorti-Passerini C; Massaia M; Bocchia M; Scattolin A; Billio A; Marchesi F; Trentin L; Cattaneo C; Derenzini E; Fracchiolla NS; Romano A; et alii...
Lymphadenopathy as a predictor of progression during venetoclax treatment in chronic lymphocytic leukemia. A campus chronic lymphocytic leukemia study. in Hematological oncology / Hematol Oncol. 2023 Dec;41(5):877-883. doi: 10.1002/hon.3199. Epub 2023 Jul 1.
2023
AO Cuneo
AOU Città della Salute di Torino
AOU Novara
AOU Alessandria
Laurenti L; Cuneo A; Foà R; Trentin L; Coscia M; Rigolin GM; Mattiello V; Gattei V; Sportoletti P; Scortechini I; Moia R; Gentile M; Catania G; Loseto G; Chiurazzi F; Malerba L; De Paolis MR; Angeletti I; Ferrari A; Giordano A; Baratè C; Quaresmini G; Leone MMA; Farina L; Fresa A; Piciocchi A; Vitale C; Reda G; Visentin A; et alii...
High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 - VERITAS study. in Haematologica / Haematologica. 2023 Aug 1;108(8):2091-2100. doi: 10.3324/haematol.2022.282116.
2023
AOU Alessandria
AO Cuneo
AOU Città della Salute di Torino
AO Ordine Mauriziano
ASL Cuneo 1
AOU Novara
Fazi P; Vignetti M; Piciocchi A; Cuneo A; Foà R; Guarini A; Nanni M; Neri A; De Propris MS; De Novi LA; Visentin A; Vitale C; Albano F; Molinari MC; Pietrasanta D; Mattiello V; Liberati AM; Giordano A; Gottardi D; Patrizi VB; Galieni P; Musuraca G; Deodato M; Arcari A; Tani M; Levato L; Marchetti M; Massaia M; Rigolin GM; et alii...
Predictive value on advance hodgkin lymphoma treatment outcome of end-of treatment FDG PET/CT in the HD0607 clinical trial. in Hematological oncology / Hematol Oncol. 2023 Aug;41(3):415-423. doi: 10.1002/hon.3117. Epub 2023 Jan 4.
2023
AO Cuneo
Rambaldi A; Gallamini A; Trentin L; La Nasa G; Sorasio R; Viviani S; Schiavotto C; Romano A; Pavoni C; Patti C; Picardi M; Gregianin M; Chiaravalloti A; Schillaci O; Bergesio F; Menga M; Bianchi A; Chauvie S; Fallanca F; Guerra L; Biggi A;
Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three-factor model. in American journal of hematology / Am J Hematol. 2022 May;97(5):E176-E180. doi: 10.1002/ajh.26502. Epub 2022 Feb 25.
2022
AO Cuneo
ASL Cuneo 1
AOU Città della Salute di Torino
AOU Novara
Mauro FR; Trentin L; Foa' R; Tedeschi A; Gaidano G; Cuneo A; Coscia M; Guarente V; Noto A; Ielo C; Deodato M; Del Poeta G; Stelitano C; Moia R; Giordano A; Levato L; Rigolin GM; Gentile M; Murru R; De Paoli L; Laurenti L; Vitale C; Ciolli S; Chiarenza A; Sportoletti P; Frustaci AM; Visentin A; Reda G; Giannarelli D; et alii...
Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia: A real-life campus CLL study. in American journal of hematology / Am J Hematol. 2022 Mar 1;97(3):E95-E99. doi: 10.1002/ajh.26437. Epub 2021 Dec 21.
2022
AO Cuneo
ASL Cuneo 1
AOU Città della Salute di Torino
AOU Alessandria
Cuneo A; Trentin L; Foà R; Molica S; Laurenti L; Pravato S; Marchetti M; Murru R; Gentile M; Rigolin GM; Quaglia FM; Coscia M; Piazza F; Reda G; Fresa A; Ciolli S; Scarfò L; Sportoletti P; Pietrasanta D; Vitale C; Mauro FR; Cibien F; Visentin A;
Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study. in Haematologica / Haematologica. 2022 Jun 1;107(6):1470-1473. doi: 10.3324/haematol.2021.280325.
2022
AO Cuneo
ASL Cuneo 1
AOU Città della Salute di Torino
AOU Novara
Cuneo A; Laurenti L; Ghia P; Foà R; Trentin L; Pompili M; Tedeschi A; Mauro FR; Del Poeta G; Scarfò L; Autore F; Tomasso A; Di Sevo D; Arena V; Deodato M; Ielo C; Frustaci AM; Piciocchi A; Rughini A; Cassin R; Albano F; Quaglia FM; Pennese E; Moia R; Gentile M; Murru R; Motta M; Coscia M; Visentin A; et alii...
A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study. in Blood advances / Blood Adv. 2022 Jan 11;6(1):327-338. doi: 10.1182/bloodadvances.2021005691.
2022
ASL Torino 5
ASL Biella
AO Cuneo
AOU Città della Salute di Torino
ASL Cuneo 1
AOU Novara
AOU Alessandria
Ladetto M; Pilerci S; Pinto A; Ramadan S; Marchesi F; Cavo M; Musto P; Coviello E; Romano A; Passamonti F; Corradini P; Krampera M; Tosi P; Lanza F; Candoni A; Selleri C; Conconi A; Visani G; Vallisa D; Venditti A; Gambacorti-Passerini C; Rigacci L; La Barbera EO; Corso A; Armiento D; Cilloni D; Cardinali V; Galimberti S; Bocchia M; et alii...
Secondary infections worsen the outcome of COVID-19 in patients with hematological malignancies: A report from the ITA-HEMA-COV. in Hematological oncology / Hematol Oncol. 2022 Dec;40(5):846-856. doi: 10.1002/hon.3048. Epub 2022 Aug 12.
2022
AO Cuneo
ASL Torino 5
AOU Città della Salute di Torino
Passamonti F; Arcaini L; Bruno R; Antonio Grossi P; Corradini P; Pagano L; Busca A; Giuliani N; Luppi M; Tosi P; Mohamed S; Corso A; Rigacci L; Giovanni Della Porta M; Lanza F; Venditti A; Massimo Lemoli R; Billio A; Gentile M; Falini B; Turrini M; Tafuri A; Morotti A; Chiara Tisi M; Galimberti S; Coviello E; Trentin L; Cuneo A; Bocchia M; et alii...
Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL. in Journal of hematology & oncology / J Hematol Oncol. 2022 Aug 26;15(1):116. doi: 10.1186/s13045-022-01333-0.
2022
AO Cuneo
ASL Vercelli
ASL Cuneo 1
AOU Alessandria
Ghia P; Stamatopoulos K; Yassin M; Coscia M; Rambaldi A; Montserrat E; Foà R; Cuneo A; Carrier M; Wróbel T; Segundo LYS; Visentin A; Vitale C; Vukovic V; Wasik-Szczepanek E; Tomic K; Tonino S; Trentin L; Van Der Spek E; van Gelder M; Varettoni M; Shrestha A; Šimkovi? M; Smirnova S; Špa?ek M; Sportoletti P; Stanca O; Stavroyianni N; Te Raa D; et alii...
The complex karyotype landscape in chronic lymphocytic leukemia allows the refinement of the risk of Richter syndrome transformation. in Haematologica / Haematologica. 2022 Apr 1;107(4):868-876. doi: 10.3324/haematol.2021.278304.
2022
AO Cuneo
Visentin A; Bonaldi L; Rigolin GM; Mauro FR; Martines A; Frezzato F; Pravato S; Gargarella LR; Bardi MA; Cavallari M; Volta E; Cavazzini F; Nanni M; Facco M; Piazza F; Guarini A; Foà R; Semenzato G; Cuneo A; Trentin L;
Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study. in Frontiers in oncology / Front Oncol. 2022 Nov 21;12:1033413. doi: 10.3389/fonc.2022.1033413. eCollection 2022.
2022
AO Cuneo
AOU Città della Salute di Torino
AOU Alessandria
Laurenti L; Trentin L; Cuneo A; Foà R; Ghia P; Coscia M; Reda G; Scarfò L; Angotzi F; Cellini A; Pravato S; Molica S; Marchetti M; Murru R; Gozzetti A; Gentile M; Rigolin GM; Quaglia FM; Sanna A; Sportoletti P; Cibien F; Mattiello V; Mauro FR; Catania G; Fresa A; Vitale C; Visentin A;
Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report. in Hematological oncology / Hematol Oncol. 2021 Oct;39(4):570-574. doi: 10.1002/hon.2899. Epub 2021 Jul 13.
2021
AO Cuneo
AOU Città della Salute di Torino
AO Ordine Mauriziano
AOU Alessandria
AOU Novara
Foà R; Chiarenza A; Penna G; Gottardi D; Derenzini E; Levato L; Orsucci L; Gattei V; Gentile M; Sanna A; Gozzetti A; Olivieri J; Murru R; Baratè C; Leone M; Stefoni V; Malerba L; Ibatici A; Tisi MC; Marasca R; Chiurazzi F; Varettoni M; Farina L; Del Poeta G; Re F; De Paoli L; Foglietta M; Giordano A; Marchetti M; et alii...
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study. in American journal of hematology / Am J Hematol. 2021 May 1;96(5):E168-E171. doi: 10.1002/ajh.26127. Epub 2021 Feb 24.
2021
AO Cuneo
AOU Città della Salute di Torino
AOU Alessandria
AOU Novara
Gentile M; Gattei V; Foà R; Ferrarini M; Polliack A; Gaidano G; Trentin L; Cuneo A; Fronza G; Cutrona G; Rossi D; Di Raimondo F; Neri A; Bomben R; Biagi A; Del Giudice I; Angeletti I; Galimberti S; Rago A; Caracciolo D; Cassin R; D'Arrigo G; Mendicino F; Botta C; Martino EA; Vigna E; Zucchetto A; Rossi FM; Scortechini I; et alii...
Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib. in Cancers / Cancers (Basel). 2021 Jun 29;13(13):3240. doi: 10.3390/cancers13133240.
2021
AO Cuneo
AOU Città della Salute di Torino
AOU Novara
Trentin L; Gentile G; Girmenia C; Martelli M; Gaidano G; Foà R; Cuneo A; Tedeschi A; Molica S; Coscia M; Noto A; Guarente V; Stelitano C; Del Poeta G; Giordano A; Rigolin GM; De Paoli L; Murru R; Gentile M; Levato L; Ielo C; Laurenti L; Ciolli S; Vitale C; Frustaci AM; Chiarenza A; Sportoletti P; Reda G; Visentin A; et alii...
Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs. in Blood / Blood. 2021 Jun 24;137(25):3507-3517. doi: 10.1182/blood.2020008201.
2021
AO Cuneo
AOU Città della Salute di Torino
AOU Alessandria
AOU Novara
Griggio V; Vitale C; Coscia M; Salvetti C; Gaidano G; Mauro FR; Foà R; Boccadoro M; Scarfò L; Cuneo A; Tedeschi A; Reda G; Orsucci L; Trentin L; De Paoli L; Montalbano MC; Boccellato E; Perutelli F; Marchetti M; Pennese E; Gentile M; Rivela P; Murru R; Laurenti L; Rigolin GM; Vassallo F; Cassin R; Porrazzo M; Schiattone L; et alii...
Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study. in Cancers / Cancers (Basel). 2021 Dec 31;14(1):207. doi: 10.3390/cancers14010207.
2021
AO Cuneo
ASL Cuneo 1
AOU Città della Salute di Torino
AO Ordine Mauriziano
AOU Alessandria
AOU Novara
Piciocchi A; Cuneo A; Foà R; Fazi P; Neri A; Guarini A; Rigolin GM; Nanni M; De Propris MS; Della Starza I; Raponi S; Del Giudice I; Murru R; Ruocco V; Ibatici A; Varettoni M; Laurenti L; Chiarenza A; Zinzani PL; Gentile M; Molinari A; Gozzetti A; Tani M; Musuraca G; Gottardi D; Re F; Orsucci L; Liberati AM; Ilariucci F; et alii...
Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab: the GIMEMA LLC1114 phase 2 study. in Blood / Blood. 2021 Dec 23;138(25):2727-2730. doi: 10.1182/blood.2021011883.
2021
AO Cuneo
AOU Alessandria
Guarini A; Mauro FR; Cuneo A; Vignetti M; Peragine N; Mariglia P; Nanni M; Marchetti M; Trentin L; Molica S; Sportoletti P; Reda G; Albano F; Arena V; Piciocchi A; Cafforio L; Ilari C; Raponi S; Cura F; García-Jacobo RE; Foà R; Melandri A; Bardi A; Del Giudice I; Rigolin GM;
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study. in Leukemia / Leukemia. 2021 Dec;35(12):3444-3454. doi: 10.1038/s41375-021-01450-8. Epub 2021 Nov 1.
2021
AO Cuneo
AOU Città della Salute di Torino
AOU Alessandria
AOU Novara
Ghia P; Stamatopoulos K; Montserrat E; Cuneo A; Foà R; Rambaldi A; Coscia M; Yassin M; Vitale C; van Kampen R; San Segundo LY; Wróbel T; Wasik-Szczepanek E; Varettoni M; Visentin A; Trentin L; Van Der Spek E; van Gelder M; Te Raa D; Tonino SH; Tadmor T; Stavroyianni N; Stanca O; Sportoletti P; Šimkovi? M; Špa?ek M; Shrestha A; Saghumyan G; Reda G; et alii...
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases. in American journal of hematology / Am J Hematol. 2021 Aug 1;96(8):E306-E310. doi: 10.1002/ajh.26235. Epub 2021 May 25.
2021
AO Cuneo
AOU Città della Salute di Torino
AOU Alessandria
AOU Novara
Gentile M; Gattei V; Ferrarini M; Foà R; Polliack A; Trentin L; Cuneo A; Gaidano G; Di Raimondo F; Rossi D; Olivieri J; Jaksic O; Bomben R; Neri A; Fronza G; Rago A; Angeletti I; Cutrona G; Del Giudice I; Biagi A; Galimberti S; D'Arrigo G; Al-Janazreh H; Martino EA; Vigna E; Tripepi G; Zucchetto A; Rossi FM; Recchia AG; et alii...
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials. in American journal of hematology / Am J Hematol. 2021 Aug 1;96(8):E269-E272. doi: 10.1002/ajh.26201. Epub 2021 May 3.
2021
AO Cuneo
AOU Città della Salute di Torino
AOU Alessandria
AOU Novara
D Arrigo G; Murru R; Gentile M; Gattei V; Polliack A; Trentin L; Gaidano G; Di Raimondo F; Cuneo A; Cutrona G; Rossi D; Menichini P; Olivieri J; Fronza G; Monti P; Del Giudice I; Bomben R; Neri A; Angeletti I; Biagi A; Rago A; Martino EA; Cassin R; Galimberti S; Foà R; Ferrarini M; Scortechini I; Rossi FM; Zucchetto A; et alii...
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases. in European journal of haematology / Eur J Haematol. 2021 Apr;106(4):493-499. doi: 10.1111/ejh.13573. Epub 2021 Jan 28.
2021
AO Cuneo
AOU Città della Salute di Torino
AOU Alessandria
AOU Novara
Gentile M; Gattei V; Ferrarini M; Foà R; Trentin L; Polliack A; Gaidano G; Cuneo A; Di Raimondo F; Rossi D; Jaksic O; Monti P; Cutrona G; Bomben R; Neri A; Fronza G; Menichini P; Biagi A; Del Giudice I; Angeletti I; Rago A; Galimberti S; Cassin R; D'Arrigo G; Mendicino F; Martino EA; Vigna E; Al-Janazreh H; Zucchetto A; et alii...
TH2/TH1 Shift Under Ibrutinib Treatment in Chronic Lymphocytic Leukemia. in Frontiers in oncology / Front Oncol. 2021 Apr 15;11:637186. doi: 10.3389/fonc.2021.637186. eCollection 2021.
2021
AO Cuneo
Puzzolo MC; Del Giudice I; Peragine N; Mariglia P; De Propris MS; Cappelli LV; Trentin L; Reda G; Cuneo A; Molica S; Piciocchi A; Arena V; Mauro FR; Guarini A; Foà R;
Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib-rituximab. in Blood cancer journal / Blood Cancer J. 2020 Sep 16;10(9):92. doi: 10.1038/s41408-020-00358-3.
2020
AOU Città della Salute di Torino
AO Cuneo
AOU Alessandria
AOU Novara
Gattei V; Morabito F; Ferrarini M; Gaidano G; Cuneo A; Foà R; Trentin L; Fronza G; Cutrona G; Di Raimondo F; Angeletti I; Bomben R; Neri A; D'Arrigo G; Tripepi G; Vitale C; Al-Janazreh H; Rossi FM; Zucchetto A; Scortechini I; Consoli U; Loseto G; Pietrasanta D; Bossio S; Moia R; Recchia AG; Lucia E; Mendicino F; Vigna E; et alii...
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. in Leukemia / Leukemia. 2020 Sep;34(9):2354-2363. doi: 10.1038/s41375-020-0959-x. Epub 2020 Jul 9.
2020
AO Cuneo
AOU Città della Salute di Torino
AOU Alessandria
AOU Novara
Foà R; Rambaldi A; Montserrat E; Rossi G; Stamatopoulos K; Coscia M; Stavroyianni N; Strugov V; Tam C; Zdrenghea M; Shah N; Shrestha A; Stanca O; Ortiz Pareja M; Papaioannou M; Rossi D; Kalashnikova O; Hakobyan Y; Doubek M; Enrico A; Dimou M; Andres M; Chiarenza A; Nikitin E; Dos Santos G; Barna G; Yassin M; Pocali B; Sportoletti P; et alii...
Early serum TARC reduction predicts prognosis in advanced-stage Hodgkin lymphoma patients treated with a PET-adapted strategy. in Hematological oncology / Hematol Oncol. 2020 Oct;38(4):501-508. doi: 10.1002/hon.2775. Epub 2020 Jul 30.
2020
AO Ordine Mauriziano
AO Cuneo
Gallamini A; Gianni AM; Corradini P; Galbiati M; Ferreri AJM; Farina L; Zanotti R; Cimminiello M; Tarella C; Gottardi D; Guidetti A; Sorasio R; Trentin L; Romano A; Patti C; Rossi A; Taverna F; Pavoni C; Mazzocchi A; Viviani S; Rambaldi A;
Consolidation Radiotherapy Could Be Safely Omitted in Advanced Hodgkin Lymphoma With Large Nodal Mass in Complete Metabolic Response After ABVD: Final Analysis of the Randomized GITIL/FIL HD0607 Trial. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2020 Nov 20;38(33):3905-3913. doi: 10.1200/JCO.20.00935. Epub 2020 Sep 18.
2020
AO Cuneo
Rambaldi A; Tarella C; Guerra L; Fallanca F; Ficola U; Mulé A; Viero P; Schiavotto C; Cimminiello M; Pavoni C; Zanotti R; Sorasio R; Battistini R; Chauvie S; Gini G; Trentin L; Bolis S; Oppi S; Viviani S; Cantonetti M; Romano A; Picardi M; Patti C; Gallamini A; Rossi A;
Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study. in Cancer medicine / Cancer Med. 2020 Nov;9(22):8468-8479. doi: 10.1002/cam4.3470. Epub 2020 Sep 24.
2020
ASL Asti
AOU Città della Salute di Torino
ASL Vercelli
AO Cuneo
AOU Novara
Vignetti M; Foà R; Ghia P; Cimino G; Cavallari M; Cucci R; de la Serna J; Ferrarini I; Medina Perez A; Mauro FR; Coscia M; Di Raimondo F; Farina L; Molica S; Gaidano G; Doubek M; Ilariucci F; Tedeschi A; Marchetti M; Spacek M; Trentin L; Billio A; Ujjani CS; Roeker L; Orlandi EM; Schuster SJ; Shah NN; Sehgal AR; Pu JJ; et alii...
The neutrophil to lymphocyte ratio (NLR) and the presence of large nodal mass are independent predictors of early response: A subanalysis of the prospective phase II PET-2-adapted HD0607 trial. in Cancer medicine / Cancer Med. 2020 Dec;9(23):8735-8746. doi: 10.1002/cam4.3396. Epub 2020 Nov 6.
2020
AOU San Luigi di Orbassano
AO Cuneo
AOU Città della Salute di Torino
Gallamini A; Rambaldi A; Massimo Gianni A; Chauvie S; Biggi A; Ferreri AJM; Viero P; Gini G; Zanotti R; Parvis G; Schiavotto C; Cimminiello M; Corradini P; Zoli V; Gavarotti P; Bolis S; Trentin L; La Nasa G; Cantonetti M; Picardi M; Rossi A; Patti C; Viviani S; Tarella C; Di Raimondo F; Pavoni C; Romano A;
A scoring system to predict the risk of atrial fibrillation in chronic lymphocytic leukemia. in Hematological oncology / Hematol Oncol. 2019 Oct;37(4):508-512. doi: 10.1002/hon.2655. Epub 2019 Aug 5.
2019
AOU Città della Salute di Torino
AO Cuneo
Semenzato G; Trentin L; Foà R; Cuneo A; Coscia M; Cassin R; Laurenti L; Tedeschi A; Cesini L; Piazza F; Rigolin GM; Molica S; Vitale C; Reda G; Autore F; Mauro FR; Deodato M; Visentin A;
Venetoclax in CLL patients who progress after B-cell Receptor inhibitor treatment: a retrospective multi-centre Italian experience. in British journal of haematology / Br J Haematol. 2019 Oct;187(1):e8-e11. doi: 10.1111/bjh.16123. Epub 2019 Jul 31.
2019
AOU Città della Salute di Torino
AO Cuneo
Laurenti L; Foà R; Cuneo A; Scarfò L; Tedeschi A; Efremov DG; D'Arena G; Gentile M; Levato L; Murru R; Sportoletti P; Coscia M; Ciolli S; Ibatici A; Reda G; Rigolin GM; Del Poeta G; Trentin L; Schiattone L; Mauro FR; Frustaci A; Piciocchi A; Autore F; Morelli F; Innocenti I;
Elevated Lactate Dehydrogenase Has Prognostic Relevance in Treatment-Naïve Patients Affected by Chronic Lymphocytic Leukemia with Trisomy 12. in Cancers / Cancers (Basel). 2019 Jun 26;11(7):896. doi: 10.3390/cancers11070896.
2019
AOU Città della Salute di Torino
AO Cuneo
Laurenti L; Ferrajoli A; Foà R; Sica S; Visentin A; Reda G; Tisi MC; Vitale C; Rigolin GM; Ferretti A; Efremov DG; Vincelli D; Murru R; D'Arena G; Falcucci P; Molica S; Morabito F; Gentile M; Frustaci AM; Mauro FR; Gozzetti A; Cuneo A; Visco C; Coscia M; Cortelezzi A; Trentin L; Corrente F; Innocenti I; Strati P; et alii...
Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphoma. in Oncotarget / Oncotarget. 2018 May 4;9(34):23443-23450. doi: 10.18632/oncotarget.25215. eCollection 2018 May 4.
2018
AO Cuneo
AOU Città della Salute di Torino
Zinzani PL; Trentin L; Morello L; Argnani L; Desabbata G; Scortechini I; Castellino C; Mastrullo L; Marasca R; Santambrogio E; Vanazzi A; D'Alò F; Rigolin GM; Ilariucci F; Molica S; Cascavilla N; Tosi P; Di Renzo N; Baldini L; Zilioli VR; Paolini R; Visco C; Merli M; Pisani F; Spina F; Ferrero S; Volpetti S; Spina M; Gotti M; et alii...
Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607 Trial. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2018 Feb 10;36(5):454-462. doi: 10.1200/JCO.2017.75.2543. Epub 2018 Jan 23.
2018
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AO Cuneo
AOU Città della Salute di Torino
Rambaldi A; Gianni AM; Pavoni C; Chauvie S; Bergesio F; Prosperini G; Chiaravalloti A; Gregianin M; Ficola U; Fallanca F; Biggi A; Avigdor A; Billio A; Miglino M; Viero P; Ferreri AJM; Gini G; Zanotti R; Parvis G; Schiavotto C; Cimminiello M; Corradini P; Gavarotti P; Gottardi D; Battistini R; Rapezzi D; Bolis S; Trentin L; La Nasa G; et alii...
The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study. in The Lancet. Haematology / Lancet Haematol. 2016 Oct;3(10):e467-e479. doi: 10.1016/S2352-3026(16)30108-9.
2016
AO Cuneo
AOU Città della Salute di Torino
Pileri SA; d'Amore F; Zinzani PL; Gascoyne RD; Broccoli A; Argnani L; Steidl C; Subocz E; Rybka J; Tajer J; Kulikowski W; Zaucha JM; Hamilton-Dutoit S; Kamper P; Piccaluga PP; Borra A; Stelitano C; Trentin L; Patti C; Romano A; Levis A; Merli F; Vitolo U; Rigacci L; Biggi A; Sista MT; Fanti S; Fuligni F; Agati P; et alii...
Randomized Trial Comparing R-CHOP Versus High-Dose Sequential Chemotherapy in High-Risk Patients With Diffuse Large B-Cell Lymphomas. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2016 Nov 20;34(33):4015-4022. doi: 10.1200/JCO.2016.67.2980. Epub 2016 Oct 31.
2016
AO Cuneo
AOU Città della Salute di Torino
AO Ordine Mauriziano
Rambaldi A; Boschini C; Delaini F; Masciulli A; Pileri S; Tabanelli V; Bruna R; Chilosi M; Falorio S; Flenghi L; Frezzato M; Trentin L; Gini G; La Nasa G; Benedetti F; Ferreri AJ; Di Raimondo F; Castellino C; Negri G; Piccin A; Billio A; Zoli V; Zanni M; Mulé A; Corradini P; Patti C; Di Nicola M; Gritti G; Rossi A; et alii...
The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale. in Haematologica / Haematologica. 2014 Jun;99(6):1107-13. doi: 10.3324/haematol.2013.103218. Epub 2014 Mar 21.
2014
AO Cuneo
Gallamini A; Barrington SF; Hutchings M; Luminari S; Salvi F; Viviani S; Bolis S; Rusconi C; Brice P; Dann EJ; Trentin L; Casasnovas O; Pulsoni A; Coleman M; Hofman MS; Rigacci L; Seymour JF; Zaucha JM; Loft A; Mikhaeel GN; Biggi A; Meignan M; Kostakoglu L; Gregianin M; Chauvie S;
Upstaging by pet-ascertained bone and bone marrow involvement in hodgkin lymphoma-definitions matter in Haematologica
2013
AO Cuneo
Borra A; El-Galaly TC; Zaucha JM; Rigacci L; Rapezzi D; Rago A; Bolis S; Gavarotti P; Rusconi C; Trentin L; Stelitano C; Biggi A; Gormsen LC; D'Amore F; Hutchings M; Gallamini A;
Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2007 Aug 20;25(24):3746-52. doi: 10.1200/JCO.2007.11.6525. Epub 2007 Jul 23.
2007
AO Cuneo
Biggi A; Vitolo U; Stelitano C; D'Amore F; Di Raimondo F; Loft A; Patti C; Hansen M; Merli F; Specht L; Rigacci L; Hutchings M; Gallamini A; Sancetta R; Trentin L; Luminari S; Iannitto E; Viviani S; Pierri I; Levis A;
The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. in Haematologica / Haematologica. 2006 Apr;91(4):475-81.
2006
AO Cuneo
Levis A; Torchio P; Gregianin M; Pelosi E; Versari A; Castagnoli A; Biggi A; Tavera S; Stelitano C; Trentin L; Iannitto E; Sancetta R; Vitolo U; Luminari S; Capodanno I; Bosi A; Nassi L; Merli F; Gallamini A; Rigacci L;